Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Ligand Pharm Cmn (LGND) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 2,176,110
  • Shares Outstanding, K 20,850
  • Annual Sales, $ 71,910 K
  • Annual Income, $ 257,310 K
  • 36-Month Beta 1.37
  • Price/Sales 30.26
  • Price/Book 6.42

Price Performance

See More
Period Period Low Period High Performance
1-Month
91.36 +16.58%
on 11/07/16
110.83 -3.90%
on 11/14/16
+15.12 (+16.54%)
since 11/04/16
3-Month
87.50 +21.73%
on 11/04/16
118.65 -10.23%
on 09/21/16
+0.32 (+0.30%)
since 09/02/16
52-Week
82.06 +29.80%
on 02/11/16
139.79 -23.81%
on 08/01/16
-0.68 (-0.63%)
since 12/04/15

Most Recent Stories

More News
LGND NOTICE: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors of Important Deadline in Class Action Filed by Firm - LGND

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ:LGND) from November 9, 2015 through November 14, 2016, both...

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / December 1, 2016 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ:...

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / November 30, 2016 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ:...

Robbins Arroyo LLP: Ligand Pharmaceuticals Incorporated (LGND) Misled Shareholders According to a Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Ligand Pharmaceuticals Incorporated (NASDAQGM: LGND) in the U.S. District Court for...

Lawsuit for Investors in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) over alleged Violations of Securities Laws announced by Shareholders Foundation

The Shareholders Foundation, Inc. announces that a lawsuit was filed in California on behalf of certain purchasers of shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) over alleged Securities Laws Violations...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017

NEW YORK, NY / ACCESSWIRE / November 29, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated ("Ligand" or...

SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 28, 2016 / Lundin Law PC, a shareholder rights firm announces a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ:...

SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact Brower Piven Before The Lead Plaintiff Deadline - LGND

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of...

LGND SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Ligand Pharmaceuticals Inc. and a Lead Plaintiff Deadline of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc....

LGND LOSS ALERT: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors of Important Deadline in Class Action Filed by Firm- LGND

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ: LGND) of the important January 17, 2017 lead plaintiff deadline in the class...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Support & Resistance

2nd Resistance Point 111.06
1st Resistance Point 108.78
Last Price 106.51
1st Support Level 104.22
2nd Support Level 101.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.